vs
Apellis Pharmaceuticals, Inc.（APLS）与ZIPRECRUITER, INC.（ZIP）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是ZIPRECRUITER, INC.的1.8倍（$199.9M vs $111.7M），ZIPRECRUITER, INC.净利率更高（-0.7% vs -29.5%，领先28.7%），ZIPRECRUITER, INC.同比增速更快（0.6% vs -5.9%），ZIPRECRUITER, INC.自由现金流更多（$7.6M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -4.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
ZipRecruiter, Inc.是一家美国线上招聘平台企业，主打面向求职者与招聘方的求职招聘匹配服务，为双方提供高效对接的人才服务市场，帮助求职者快速找到适配岗位，也助力企业高效完成招聘需求。
APLS vs ZIP — 直观对比
营收规模更大
APLS
是对方的1.8倍
$111.7M
营收增速更快
ZIP
高出6.5%
-5.9%
净利率更高
ZIP
高出28.7%
-29.5%
自由现金流更多
ZIP
多$21.9M
$-14.3M
两年增速更快
APLS
近两年复合增速
-4.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $111.7M |
| 净利润 | $-59.0M | $-835.0K |
| 毛利率 | — | 89.1% |
| 营业利润率 | -25.6% | 3.6% |
| 净利率 | -29.5% | -0.7% |
| 营收同比 | -5.9% | 0.6% |
| 净利润同比 | -62.2% | 92.3% |
| 每股收益（稀释后） | $-0.40 | $-0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSZIP
| Q4 25 | $199.9M | $111.7M | ||
| Q3 25 | $458.6M | $115.0M | ||
| Q2 25 | $178.5M | $112.2M | ||
| Q1 25 | $166.8M | $110.1M | ||
| Q4 24 | $212.5M | $111.0M | ||
| Q3 24 | $196.8M | $117.1M | ||
| Q2 24 | $199.7M | $123.7M | ||
| Q1 24 | $172.3M | $122.2M |
净利润APLSZIP
| Q4 25 | $-59.0M | $-835.0K | ||
| Q3 25 | $215.7M | $-9.8M | ||
| Q2 25 | $-42.2M | $-9.5M | ||
| Q1 25 | $-92.2M | $-12.8M | ||
| Q4 24 | $-36.4M | $-10.8M | ||
| Q3 24 | $-57.4M | $-2.6M | ||
| Q2 24 | $-37.7M | $7.0M | ||
| Q1 24 | $-66.4M | $-6.5M |
毛利率APLSZIP
| Q4 25 | — | 89.1% | ||
| Q3 25 | — | 89.1% | ||
| Q2 25 | — | 89.3% | ||
| Q1 25 | — | 89.4% | ||
| Q4 24 | — | 89.6% | ||
| Q3 24 | — | 89.4% | ||
| Q2 24 | — | 89.5% | ||
| Q1 24 | — | 89.1% |
营业利润率APLSZIP
| Q4 25 | -25.6% | 3.6% | ||
| Q3 25 | 48.7% | -4.4% | ||
| Q2 25 | -18.6% | -5.9% | ||
| Q1 25 | -50.0% | -10.6% | ||
| Q4 24 | -12.3% | -3.6% | ||
| Q3 24 | -24.0% | -2.8% | ||
| Q2 24 | -14.7% | 7.6% | ||
| Q1 24 | -36.0% | -0.7% |
净利率APLSZIP
| Q4 25 | -29.5% | -0.7% | ||
| Q3 25 | 47.0% | -8.5% | ||
| Q2 25 | -23.6% | -8.5% | ||
| Q1 25 | -55.3% | -11.7% | ||
| Q4 24 | -17.1% | -9.7% | ||
| Q3 24 | -29.2% | -2.2% | ||
| Q2 24 | -18.9% | 5.7% | ||
| Q1 24 | -38.5% | -5.3% |
每股收益（稀释后）APLSZIP
| Q4 25 | $-0.40 | $-0.03 | ||
| Q3 25 | $1.67 | $-0.11 | ||
| Q2 25 | $-0.33 | $-0.10 | ||
| Q1 25 | $-0.74 | $-0.13 | ||
| Q4 24 | $-0.30 | $-0.10 | ||
| Q3 24 | $-0.46 | $-0.03 | ||
| Q2 24 | $-0.30 | $0.07 | ||
| Q1 24 | $-0.54 | $-0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $188.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $-77.2M |
| 总资产 | $1.1B | $569.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSZIP
| Q4 25 | $466.2M | $188.0M | ||
| Q3 25 | $479.2M | $211.8M | ||
| Q2 25 | $370.0M | $203.5M | ||
| Q1 25 | $358.4M | $221.1M | ||
| Q4 24 | $411.3M | $218.4M | ||
| Q3 24 | $396.9M | $225.6M | ||
| Q2 24 | $360.1M | $271.7M | ||
| Q1 24 | $325.9M | $282.5M |
总债务APLSZIP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSZIP
| Q4 25 | $370.1M | $-77.2M | ||
| Q3 25 | $401.2M | $-76.1M | ||
| Q2 25 | $156.3M | $-65.9M | ||
| Q1 25 | $164.2M | $-11.3M | ||
| Q4 24 | $228.5M | $13.4M | ||
| Q3 24 | $237.1M | $13.6M | ||
| Q2 24 | $264.3M | $24.4M | ||
| Q1 24 | $266.7M | $12.7M |
总资产APLSZIP
| Q4 25 | $1.1B | $569.7M | ||
| Q3 25 | $1.1B | $573.6M | ||
| Q2 25 | $821.4M | $592.4M | ||
| Q1 25 | $807.3M | $629.4M | ||
| Q4 24 | $885.1M | $664.1M | ||
| Q3 24 | $901.9M | $652.0M | ||
| Q2 24 | $904.5M | $665.3M | ||
| Q1 24 | $831.9M | $662.4M |
负债/权益比APLSZIP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $7.7M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $7.6M |
| 自由现金流率自由现金流/营收 | -7.1% | 6.8% |
| 资本支出强度资本支出/营收 | 0.1% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $9.9M |
8季度趋势，按日历期对齐
经营现金流APLSZIP
| Q4 25 | $-14.2M | $7.7M | ||
| Q3 25 | $108.5M | $2.6M | ||
| Q2 25 | $4.4M | $10.5M | ||
| Q1 25 | $-53.4M | $-9.9M | ||
| Q4 24 | $19.4M | $12.5M | ||
| Q3 24 | $34.1M | $9.3M | ||
| Q2 24 | $-8.3M | $21.9M | ||
| Q1 24 | $-133.0M | $2.0M |
自由现金流APLSZIP
| Q4 25 | $-14.3M | $7.6M | ||
| Q3 25 | $108.3M | $2.2M | ||
| Q2 25 | $4.4M | $10.2M | ||
| Q1 25 | $-53.4M | $-10.2M | ||
| Q4 24 | $19.3M | $12.0M | ||
| Q3 24 | — | $9.2M | ||
| Q2 24 | $-8.4M | $21.7M | ||
| Q1 24 | $-133.3M | $1.9M |
自由现金流率APLSZIP
| Q4 25 | -7.1% | 6.8% | ||
| Q3 25 | 23.6% | 1.9% | ||
| Q2 25 | 2.5% | 9.1% | ||
| Q1 25 | -32.0% | -9.3% | ||
| Q4 24 | 9.1% | 10.8% | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | -4.2% | 17.6% | ||
| Q1 24 | -77.3% | 1.6% |
资本支出强度APLSZIP
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.2% | 0.1% |
现金转化率APLSZIP
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.12× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ZIP
| License | $84.3M | 75% |
| Services | $27.4M | 25% |
